Clinical trials: Tumor Pancreas
Pancreatic Cancer
Pancreatic Core Biopsy Needle Study in Patients Suspected of Pancreatic Malignancy
This study evaluates whether a new endoscopic ultrasonography (EUS) histology needle may improve the diagnostic yield during biopsies of pancreatic lesions
- Trial name
- PANCOBE (NCT03016637)
- Testing
- SharkCore (TM) FNB Exchange System
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Odense University Hospital
Duct Cell Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer
Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer
This phase I trial studies the side effects and best dose of gemcitabine hydrochloride in treating patients with locally advanced pancreatic cancer.
- Conditions
- Duct Cell Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01893294
- Testing
- gemcitabine hydrochloride, fluorouracil, radiation therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Intraductal Papillary Mucinous Neoplasms
Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas
1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography 2.
- Trial name
- NCT00621556
- Testing
- RG1068 (Synthetic Human Secretin)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Pancreas Cancer
The Role of Meat-borne Carcinogens in Pancreatic Cancer
We propose to recruit subjects scheduled for pancreatectomy as a treatment for pancreatic cancer. These subjects will ingest a very low dose of radiolabeled PhIP, a meat-derived carcinogen, and a small amount of resected tissue…
- Trial name
- NCT01092689
- Testing
- PhiP
- Where
- United States
- Sponsor
- University of Minnesota
Gastrointestinal Neoplasms, Cholangiocarcinoma
A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
Phase 1a - Explore safety and establish the maximum tolerated dose (MTD)/recommended dose levels for phase Ib expansion phase of BI 905711 based on the frequency of patients experiencing dose limiting toxicities (DLTs) during the…
- Conditions
- Gastrointestinal Neoplasms, Cholangiocarcinoma, Pancreatic Neoplasms
- Trial name
- NCT04137289
- Testing
- BI 905711
- Where
- 18 sites in United States, Belgium and 6 more
- Volunteers
- 110 people
- Sponsor
- Boehringer Ingelheim
Pancreas Cancer
Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) complexity, where genetic, stromal, and immunological factors all interact with each other, is responsible for the overall poor response of PDAC to chemotherapeutic agents, making this a…
- Trial name
- NCT05248750
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Catholic University of the Sacred Heart
Advanced Solid Tumors, Solid Tumors
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
This will be a Phase 1, open label, 2-sequence, crossover study to establish the BE of the current commercial formulation (Generation 3.1 talazoparib capsules) to the proposed talazoparib liquid-filled soft gelatin capsule (soft…
- Conditions
- Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer
- Trial name
- NCT04672460
- Testing
- TALZENNA capsule, Talazoparib soft gel capsule
- Where
- 31 sites in United States, Australia
- Volunteers
- 73 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Pancreatic Adenocarcinoma
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in…
- Conditions
- Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT05585320
- Testing
- IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
- Where
- 20 sites in United States
- Volunteers
- 209 people
- Sponsor
- Immuneering Corporation
Pancreatic Cancer
Influence of Local Anesthetic Administration on the Cancer Recurrence Rate After Pancreatic Oncologic Surgery
Study aims to compare the influence of intravenous lidocaine and peridural ropivacaine on postoperative long and short term outcome in patients with pancreatic cancer undergoing surgery.
- Trial name
- NCT04449289
- Testing
- Intravenous lidocaine, Epidural ropivacaine
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Adenocarcinoma
Personalised Therapy for Metastatic ADPC Determined by Genetic Testing and Avatar Model Generation
This is a multicenter, open label, randomised phase II clinical trial for patients with metastatic adenocarcinoma of the pancreas.
- Trial name
- AVATAR (NCT02795650)
- Testing
- Personalised treatment, Treatment chosen per investigator´s judge
- Where
- 5 sites in Spain
- Volunteers
- 146 people
- Sponsor
- Hospital Universitario de Fuenlabrada
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8
- Trial name
- NCT05040360
- Testing
- Capecitabine, Temozolomide
- Where
- 448 sites in United States, Mexico and 1 more
- Volunteers
- 141 people
- Sponsor
- SWOG Cancer Research Network
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Insulinoma, Nesidioblastosis
68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-exendin-4 in insulinoma and nesidioblastosis patients.
- Trial name
- NCT02560376
- Testing
- 68Ga-NOTA-exendin-4
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Pancreas Cancer, Cholangiocarcinoma
Radiofrequency Ablation for Biliopancreatic Malignancy
This phase-2 study aims to evaluate feasibility, safety and efficacy of thermal ablation of biliary obstructive malignancies by means of radiofrequency ablation (RFA, ELRA, StarMed) during endoscopic retrograde…
- Conditions
- Pancreas Cancer, Cholangiocarcinoma, Obstructive Jaundice
- Trial name
- IGNITE-1 (NCT02468076)
- Testing
- Radiofrequency ablation (StarMed)
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
This phase I trial studies the side effects and best dose of bosentan and how well it works when given together with gemcitabine and nab-paclitaxel for the treatment of pancreatic cancer that cannot be removed by surgery…
- Conditions
- Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
- Trial name
- NCT04158635
- Testing
- Bosentan, Gemcitabine, Nab-paclitaxel
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- City of Hope Medical Center
Resectable Prancreas Carcinoma
Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma
In this multicenter study, patients with resectable pancreatic carcinoma will be treated with (a) surgery followed by 6 cycles gemcitabine or (b) 4-6 cycles FOLFIRINOX followed by surgery followed by 4-6 cycles FOLFIRINOX.
- Trial name
- NCT02172976
- Testing
- Gemcitabine, Oxaliplatin, 5-Fluorouracil
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Krankenhaus Nordwest
Pancreatic Carcinoma, Cholangiocarcinoma
In This Study, a Retrospective Analysis Was Conducted to Explore the Risk Factors for Patients Undergoing Pancreaticoduodenal Surgery (PD) to Achieve TO, and a Nomogram Prediction Model Was Further Established to Promote the Standardization and Standardization of PD Surgical Quality Evaluation.
This study is committed TO exploring the risk factors affecting patients receiving pancreaticoduodenal surgery (PD) to achieve TO by retrospective analysis of clinical data of patients receiving PD surgery in Changzhou Second…
- Conditions
- Pancreatic Carcinoma, Cholangiocarcinoma, Pancreaticoduodenectomy
- Trial name
- NCT06763250
- Where
- China
- Volunteers
- 280 people
- Sponsor
- luokai zhang
Pancreatic Cancer
Chyle Leak After Pancreatic Operation
With the development of pancreatic surgery, the surgeon has put more emphasis on chylous fistula as the postoperative complications in recent years.
- Trial name
- NCT03127150
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pancreatic Neuroendocrine Tumor
Neoadjuvant PRRT With Y-90-DOTATOC in pNET
Neuroendocrine tumors (NETs) are relatively rare tumors, mainly originating from the digestive system, that tend to be slow growing and are often diagnosed when metastatic.
- Trial name
- NeoNet (NCT05568017)
- Testing
- peptide receptor radionuclide therapy with Y-90-DOTATOC
- Where
- Italy
- Volunteers
- 11 people
- Sponsor
- European Institute of Oncology
Pancreatic Carcinoma
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier…
- Trial name
- NCT06271291
- Testing
- Non-Interventional Study
- Where
- 11 sites in United States
- Volunteers
- 30,000 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.